- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371719
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial (BALANCE)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine whether, in men with post-prostatectomy prostate-specific antigen (PSA) recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone.
SECONDARY OBJECTIVES:
I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate cancer (luminal A or basal, luminal B) which derive the greatest benefit from anti-androgen therapy.
II. To assess overall survival. III. To assess cancer-specific mortality. IV. To assess metastasis-free survival. V. To assess distant metastasis. VI. To assess local-regional progression. VII. To assess PSA nadir during first year of treatment and prior to initiation of any hormonal salvage therapy.
VIII. To assess initiation of salvage hormonal therapy. IX. To assess PSA with a non-castrate testosterone at 1 and 3 years post randomization: PSA < 0.1 ng/ml and testosterone >= 50 ng/dl.
X. To assess acute and late physician-reported morbidity (per the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) after SRT +/- apalutamide.
XI. To assess acute and late patient-reported symptomatic adverse events morbidity (per the patient reported outcomes [PRO]-CTCAE) after SRT +/- apalutamide.
XII. To assess testosterone levels at 3, 6, 9, 12, and 36 months post randomization.
EXPLORATORY OBJECTIVE:
I. To assess the prognostic and predictive value of the genomic classifier Decipher.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive placebo orally (PO) once daily (QD) on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive apalutamide PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years, and then yearly thereafter.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 2R9
- The Research Institute of the McGill University Health Centre (MUHC)
-
Montreal, Quebec, Canada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Québec, Quebec, Canada, G1R 2J6
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85297
- Arizona Center for Cancer Care - Gilbert
-
Peoria, Arizona, United States, 85381
- Arizona Center for Cancer Care-Peoria
-
Scottsdale, Arizona, United States, 85258
- Arizona Center for Cancer Care - Scottsdale
-
Surprise, Arizona, United States, 85374
- Arizona Center for Cancer Care-Surprise
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, United States, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Greenbrae, California, United States, 94904
- Marin General Hospital
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
Los Angeles, California, United States, 90033
- Los Angeles General Medical Center
-
Roseville, California, United States, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Sacramento, California, United States, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
Truckee, California, United States, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Vallejo, California, United States, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, United States, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, United States, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, United States, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, United States, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, United States, 80528
- Cancer Care and Hematology-Fort Collins
-
Glenwood Springs, Colorado, United States, 81601
- Valley View Hospital Cancer Center
-
Greeley, Colorado, United States, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, United States, 80538
- Medical Center of the Rockies
-
-
Connecticut
-
Stamford, Connecticut, United States, 06904
- Stamford Hospital/Bennett Cancer Center
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, United States, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, United States, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20037
- George Washington University Medical Center
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- AdventHealth Altamonte
-
Fort Myers, Florida, United States, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Kissimmee, Florida, United States, 34744
- AdventHealth Kissimmee
-
Orlando, Florida, United States, 32803
- AdventHealth Orlando
-
Orlando, Florida, United States, 32822
- AdventHealth East Orlando
-
Weston, Florida, United States, 33331
- Cleveland Clinic-Weston
-
Winter Park, Florida, United States, 32792
- AdventHealth Winter Park
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, United States, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, United States, 30303
- Grady Health System
-
Atlanta, Georgia, United States, 30342
- Northside Hospital
-
Augusta, Georgia, United States, 30912
- Augusta University Medical Center
-
Savannah, Georgia, United States, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, United States, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, United States, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, United States, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, United States, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois
-
Chicago, Illinois, United States, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, United States, 62401
- Crossroads Cancer Center
-
Hines, Illinois, United States, 60141
- Edward Hines Jr VA Hospital
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Peoria, Illinois, United States, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, United States, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, United States, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, United States, 62702
- Springfield Clinic
-
Springfield, Illinois, United States, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46805
- Parkview Hospital Randallia
-
Fort Wayne, Indiana, United States, 46845
- Parkview Regional Medical Center
-
Goshen, Indiana, United States, 46526
- Goshen Center for Cancer Care
-
Richmond, Indiana, United States, 47374
- Reid Health
-
-
Iowa
-
Clive, Iowa, United States, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, United States, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, United States, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, United States, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, United States, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Cancer Center
-
Olathe, Kansas, United States, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, United States, 66210
- University of Kansas Cancer Center-Overland Park
-
Salina, Kansas, United States, 67401
- Salina Regional Health Center
-
Westwood, Kansas, United States, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Mary Bird Perkins Cancer Center
-
Metairie, Louisiana, United States, 70006
- East Jefferson General Hospital
-
Metairie, Louisiana, United States, 70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
-
Maine
-
Bath, Maine, United States, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, United States, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, United States, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, United States, 04412
- Lafayette Family Cancer Center-EMMC
-
Norway, Maine, United States, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, United States, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, United States, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, United States, 04073
- MaineHealth Cancer Care Center of York County
-
Sanford, Maine, United States, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, United States, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, United States, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, United States, 21229
- Saint Agnes Hospital
-
Columbia, Maryland, United States, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, United States, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Lahey Hospital and Medical Center
-
Lowell, Massachusetts, United States, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, United States, 49017
- Bronson Battle Creek
-
Brighton, Michigan, United States, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, United States, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, United States, 48118
- Chelsea Hospital
-
Clarkston, Michigan, United States, 48346
- Michigan Healthcare Professionals Clarkston
-
Clinton Township, Michigan, United States, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, United States, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
East Lansing, Michigan, United States, 48823
- Michigan State University
-
Farmington Hills, Michigan, United States, 48334
- Michigan Healthcare Professionals Farmington
-
Grand Rapids, Michigan, United States, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, United States, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, United States, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, United States, 48912
- University of Michigan Health - Sparrow Lansing
-
Niles, Michigan, United States, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Reed City, Michigan, United States, 49677
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, United States, 48073
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, United States, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, United States, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
Troy, Michigan, United States, 48098
- Michigan Healthcare Professionals Troy
-
Troy, Michigan, United States, 48085
- Corewell Health Beaumont Troy Hospital
-
West Bloomfield, Michigan, United States, 48322
- Henry Ford West Bloomfield Hospital
-
Wyoming, Michigan, United States, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Albert Lea, Minnesota, United States, 56007
- Mayo Clinic Health System in Albert Lea
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Hospital
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, United States, 55432
- Unity Hospital
-
Mankato, Minnesota, United States, 56001
- Mayo Clinic Health Systems-Mankato
-
Maple Grove, Minnesota, United States, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, United States, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, United States, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55454
- Health Partners Inc
-
Minneapolis, Minnesota, United States, 55417
- Minneapolis VA Medical Center
-
Monticello, Minnesota, United States, 55362
- Monticello Cancer Center
-
Robbinsdale, Minnesota, United States, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
Saint Cloud, Minnesota, United States, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Shakopee, Minnesota, United States, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, United States, 55082
- Lakeview Hospital
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, United States, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, United States, 55092
- Fairview Lakes Medical Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, United States, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, United States, 63141
- Siteman Cancer Center at West County Hospital
-
Jefferson City, Missouri, United States, 65109
- MU Health Care Goldschmidt Cancer Center
-
Kansas City, Missouri, United States, 64128
- Kansas City Veterans Affairs Medical Center
-
Kansas City, Missouri, United States, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, United States, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, United States, 65401
- Phelps Health Delbert Day Cancer Institute
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
St Louis, Missouri, United States, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, United States, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Billings, Montana, United States, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, United States, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, United States, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, United States, 68124
- Alegent Health Bergan Mercy Medical Center
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, United States, 89052
- OptumCare Cancer Care at Seven Hills
-
Henderson, Nevada, United States, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, United States, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, United States, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, United States, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, United States, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, United States, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, United States, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, United States, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, United States, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, United States, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, United States, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, United States, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, United States, 89148
- OptumCare Cancer Care at Fort Apache
-
Las Vegas, Nevada, United States, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, United States, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, United States, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, United States, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, United States, 89121
- Cancer Therapy and Integrative Medicine
-
Las Vegas, Nevada, United States, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, United States, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, United States, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, United States, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, United States, 89102
- Desert West Surgery
-
Las Vegas, Nevada, United States, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, United States, 89169
- University Cancer Center
-
Las Vegas, Nevada, United States, 89128
- Oncology Las Vegas - Tenaya
-
Pahrump, Nevada, United States, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, United States, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Concord, New Hampshire, United States, 03301
- New Hampshire Oncology Hematology PA-Concord
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, United States, 03103
- Solinsky Center for Cancer Care
-
-
New Jersey
-
Mount Holly, New Jersey, United States, 08060
- Virtua Memorial
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
Sewell, New Jersey, United States, 08080
- Sidney Kimmel Cancer Center Washington Township
-
Somerville, New Jersey, United States, 08876
- Robert Wood Johnson University Hospital Somerset
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Brooklyn, New York, United States, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Canandaigua, New York, United States, 14424
- Sands Cancer Center
-
Cooperstown, New York, United States, 13326
- Mary Imogene Bassett Hospital
-
New York, New York, United States, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, United States, 14642
- University of Rochester
-
Rochester, New York, United States, 14620
- Highland Hospital
-
Rochester, New York, United States, 14606
- Wilmot Cancer Institute Radiation Oncology at Greece
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, United States, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, United States, 10468
- James J Peters VA Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Supply, North Carolina, United States, 28462
- Novant Cancer Institute Radiation Oncology - Supply
-
Wilmington, North Carolina, United States, 28401
- Novant Health New Hanover Regional Medical Center
-
Wilmington, North Carolina, United States, 28401
- Novant Health Cancer Institute Radiation Oncology - Wilmington
-
-
Ohio
-
Akron, Ohio, United States, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, United States, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, United States, 44122
- UHHS-Chagrin Highlands Medical Center
-
Beavercreek, Ohio, United States, 45431
- Indu and Raj Soin Medical Center
-
Centerville, Ohio, United States, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, United States, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chardon, Ohio, United States, 44024
- Geauga Hospital
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, United States, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, United States, 43219
- The Mark H Zangmeister Center
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, United States, 45409
- Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, United States, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, United States, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, United States, 45840
- Orion Cancer Care
-
Franklin, Ohio, United States, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, United States, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, United States, 45331
- Wayne Hospital
-
Greenville, Ohio, United States, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, United States, 45429
- Kettering Medical Center
-
Kettering, Ohio, United States, 45409
- Greater Dayton Cancer Center
-
Kettering, Ohio, United States, 45420
- First Dayton Cancer Care
-
Mansfield, Ohio, United States, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mayfield Heights, Ohio, United States, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, United States, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, United States, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Parma, Ohio, United States, 44129
- University Hospitals Parma Medical Center
-
Ravenna, Ohio, United States, 44266
- University Hospitals Portage Medical Center
-
Sandusky, Ohio, United States, 44870
- North Coast Cancer Care
-
Sandusky, Ohio, United States, 44870
- UH Seidman Cancer Center at Firelands Regional Medical Center
-
Springfield, Ohio, United States, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, United States, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, United States, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Troy, Ohio, United States, 45373
- Upper Valley Medical Center
-
Troy, Ohio, United States, 45373
- Dayton Physicians LLC - Troy
-
West Chester, Ohio, United States, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, United States, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, United States, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, United States, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Gresham, Oregon, United States, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, United States, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, United States, 15009
- UPMC-Heritage Valley Health System Beaver
-
Bethlehem, Pennsylvania, United States, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Chadds Ford, Pennsylvania, United States, 19317
- Christiana Care Health System-Concord Health Center
-
Dunmore, Pennsylvania, United States, 18512
- Northeast Radiation Oncology Center
-
Farrell, Pennsylvania, United States, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, United States, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, United States, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Johnstown, Pennsylvania, United States, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, United States, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Monroeville, Pennsylvania, United States, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, United States, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, United States, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, United States, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, United States, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, United States, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Sayre, Pennsylvania, United States, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Seneca, Pennsylvania, United States, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, United States, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, United States, 15301
- UPMC Washington Hospital Radiation Oncology
-
West Reading, Pennsylvania, United States, 19611
- Reading Hospital
-
Willow Grove, Pennsylvania, United States, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, United States, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Greenville, South Carolina, United States, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, United States, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenwood, South Carolina, United States, 29646
- Self Regional Healthcare
-
Greer, South Carolina, United States, 29650
- Prisma Health Cancer Institute - Greer
-
Hilton Head Island, South Carolina, United States, 29926
- The Radiation Oncology Center-Hilton Head/Bluffton
-
Seneca, South Carolina, United States, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- The West Clinic - Wolf River
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78229
- Audie L Murphy VA Hospital
-
-
Utah
-
American Fork, Utah, United States, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, United States, 84720
- Sandra L Maxwell Cancer Center
-
Farmington, Utah, United States, 84025
- Farmington Health Center
-
Logan, Utah, United States, 84321
- Logan Regional Hospital
-
Murray, Utah, United States, 84107
- Intermountain Medical Center
-
Ogden, Utah, United States, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, United States, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, United States, 84065
- Riverton Hospital
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, United States, 84143
- LDS Hospital
-
St. George, Utah, United States, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Bennington, Vermont, United States, 05201
- Southwestern Vermont Medical Center
-
Berlin Corners, Vermont, United States, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, United States, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, United States, 05405
- University of Vermont and State Agricultural College
-
Saint Johnsbury, Vermont, United States, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Portsmouth, Virginia, United States, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire Veterans Administration Medical Center
-
-
Washington
-
Bellingham, Washington, United States, 98225
- PeaceHealth Saint Joseph Medical Center
-
Vancouver, Washington, United States, 98686
- Legacy Salmon Creek Hospital
-
Walla Walla, Washington, United States, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, United States, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, United States, 54701
- Marshfield Medical Center-EC Cancer Center
-
Grafton, Wisconsin, United States, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, United States, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, United States, 53142
- Aurora Cancer Care-Kenosha South
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Medical Center-Marshfield
-
Menomonee Falls, Wisconsin, United States, 53051
- Froedtert Menomonee Falls Hospital
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, United States, 53295
- Zablocki Veterans Administration Medical Center
-
Minocqua, Wisconsin, United States, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, United States, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, United States, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Rice Lake, Wisconsin, United States, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, United States, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, United States, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, United States, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, United States, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
West Allis, Wisconsin, United States, 53227
- Aurora West Allis Medical Center
-
West Bend, Wisconsin, United States, 53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Weston, Wisconsin, United States, 54476
- Marshfield Medical Center - Weston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically (histologically) proven diagnosis of prostate adenocarcinoma; prostatectomy must have been performed within 10 years prior to Step 1 registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted
Post-prostatectomy patients with a detectable serum PSA (>= 0.1, but =< 1.0 ng/mL) at study entry (within 90 days of Step 1 registration) and at least one of the following:
- Gleason score 7-10 (International Society of Urological Pathology [ISUP] grade group 2 to 5)
ISUP grade group:
- Grade group 1 = Gleason score =< 6,
- Grade group 2 = Gleason score 3 + 4 = 7,
- Grade group 3 = Gleason score 4 + 3 = 7,
- Grade group 4 = Gleason score 8,
- Grade group 5 = Gleason scores 9 and 10
- >= T3a disease
- Persistent elevation of PSA after prostatectomy measured within 90 days after surgery (PSA never became undetectable) of > 0.04 but < 0.2 ng/mL (PSA nadir)
- pN0 or pNx
- History/physical examination within 90 days prior to Step 1 registration
- Karnofsky performance status of 70-100 within 90 days prior to Step 1 registration
- Surgical formalin-fixed paraffin-embedded (FFPE) specimen must be available for submission to GenomeDx for genomic analysis on Decipher GRID platform; Note: if Decipher results have already been obtained, in lieu of tissue, results must be submitted to GenomeDx for validation and for GenomeDx to provide the subtyping needed for stratification
Prior androgen deprivation therapy (luteinizing hormone-releasing hormone [LHRH] agonist and/or non-steroidal anti-androgen) is allowed if discontinued at least 90 days prior to Step 1 registration and given for =< 90 days duration
- For example: patients on prior LHRH analogs (post-prostatectomy), the discontinuation date should be calculated based on the expected duration of the sustained release injection, not simply the injection date of the drug; for instance, if a 22.5 mg sustained release dose of leuprolide acetate is given (3 month duration), then the expected duration of such a dose would be 90 days after the injection date; for a 7.5 mg leuprolide (1 month duration), the discontinuation date would be 30 days after the injection date
- Please note: finasteride or dutasteride must be stopped before treatment starts but prior usage will not affect eligibility
- Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
- Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
- Serum albumin >= 3.0 g/dL within 90 days prior to Step 1 registration
- Glomerular filtration rate (GFR) >= 35 mL/min estimated by Cockcroft-Gault or measured directly by 24 hour urine creatinine within 90 days prior to Step 1 registration
- Serum total bilirubin =< 1.5 x upper limit of normal (ULN) (Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject is eligible) within 90 days prior to Step 1 registration
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registration
- Testosterone > 50 ng/dL within 90 days prior to Step 1 registration
- Concomitant medications known to lower the seizure threshold discontinued or substituted at least 4 weeks (30 days) prior to Step 1 registration
- The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug
- The patient must agree not to donate sperm during the study treatment and for 3 months after receiving the last dose of study drug
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
Exclusion Criteria:
- PRIOR TO STEP 1 REGISTRATION:
- Definitive clinical, radiologic, or pathologic evidence of metastatic disease (M1) or lymph node involvement (N1)
- Prior invasive malignancy (except non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years
- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
History of any of the following:
- Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year prior to Step 1 registration)
- History of documented inflammatory bowel disease
- Transmural myocardial infarction within the last 4 months prior to Step 1 registration
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to Step 1 registration
- History of any condition that in the opinion of the investigator, would preclude participation in this study
Current evidence of any of the following:
- Known gastrointestinal disorder affecting absorption of oral medications
- Active uncontrolled infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)
- Uncontrolled hypertension
- Any current condition that in the opinion of the investigator, would preclude participation in this study
- Prior whole gland ablative therapy (i.e. cryoablation or high intensity focused ultrasound [HIFU]) for prostate cancer is not allowed
- HIV positive with CD4 count < 200 cells/microliter within 30 days prior to registration
- HIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count; (Note: HIV testing is not required for eligibility for this protocol as it is self-reported; this exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART)
- Patients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapy
- PRIOR TO STEP 2 REGISTRATION:
- For patients who have not undergone prior Decipher analysis, submission of the specimen to GenomeDx should be as soon as possible after study registration (Step 1) as these results can take up 21 days after the specimen is received at GenomeDx; Step 2 registration must occur within 6 weeks (42 days) of Step 1 registration; if Decipher results have already been obtained, in lieu of tissue, results must be submitted to GenomeDx for validation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Arm 1 (radiation therapy, placebo)
Patients undergo external beam radiation therapy on day 1 for 7-8 weeks.
Beginning on day of radiation therapy, patients receive placebo PO QD on days 1-30.
Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Undergo external beam radiation therapy
Other Names:
|
|
Experimental: Arm 2 (radiation therapy, apalutamide)
Patients undergo external beam radiation therapy on day 1 for 7-8 weeks.
Beginning on day of radiation therapy, patients receive apalutamide PO QD on days 1-30.
Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Undergo external beam radiation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemical progression-free survival (bPFS)
Time Frame: From randomization to the first occurrence of a rise in PSA, clinical or radiographic local, regional, or distant metastases, or death from any cause, assessed up to 5 years
|
bPFS curves will be estimated by the Kaplan-Meier (1958) method and compared between the two treatment arms using a one-sided logrank test at the alpha = 0.12 significance level.
In addition, a multivariable Cox regression model will be fit incorporating the three stratification factors used in the randomization (surgical margins, pre-salvage radiation [SRT] PSA, and molecular subtype) as covariates to estimate the adjusted hazard ratio (HR) between the two treatment groups.
Additional regression models will be fit including other pretreatment characteristics as covariates.
The goodness-of-fit of the proportional hazards assumption will be evaluating using graphical methods (Kay, 1977), residual plots, and the global test proposed by Grambsch and Therneau (1994).
Missing covariates will be handled using multiple imputation as described in White and Royston (1982).
|
From randomization to the first occurrence of a rise in PSA, clinical or radiographic local, regional, or distant metastases, or death from any cause, assessed up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: From randomization until death from any cause, assessed up to 5 years
|
OS will be estimated by the Kaplan-Meier method and compared between treatment arms via the logrank test.
Cox regression will be used to obtain HRs for this outcome, both unadjusted and adjusted for covariates.
|
From randomization until death from any cause, assessed up to 5 years
|
|
Cancer-specific mortality (CSM)
Time Frame: From the date of randomization to the date of death due to prostate cancer, assessed up to 5 years
|
CSM will be estimated by the Kaplan-Meier method and compared between treatment arms via the logrank test.
Cox regression will be used to obtain HRs for this outcome, both unadjusted and adjusted for covariates.
A competing risks analysis will be performed treating death from prostate cancer as the event of interest and death from all other causes as a competing risk.
Cumulative incidence curves will be generated (Gooley et al., 1999; Dignam et al., 2004) along with 95% confidence intervals and compared between the two treatment arms using Gray's method (Gray, 1988).
In addition, multivariable analysis will be conducted using Fine and Gray's regression model (Fine and Gray, 1999) to derive covariate-adjusted (subdistribution) HRs and confidence intervals.
|
From the date of randomization to the date of death due to prostate cancer, assessed up to 5 years
|
|
Metastasis-free survival (MFS)
Time Frame: From randomization until distant metastasis (clinical and/or radiographic appearance of disseminated disease) or death from any cause, assessed up to 5 years
|
MFS will be estimated by the Kaplan-Meier method and compared between treatment arms via the logrank test.
Cox regression will be used to obtain HRs for this outcome, both unadjusted and adjusted for covariates.
A competing risks analysis will be performed treating death from prostate cancer as the event of interest and death from all other causes as a competing risk.
Cumulative incidence curves will be generated (Gooley et al., 1999; Dignam et al., 2004) along with 95% confidence intervals and compared between the two treatment arms using Gray's method (Gray, 1988).
In addition, multivariable analysis will be conducted using Fine and Gray's regression model (Fine and Gray, 1999) to derive covariate-adjusted (subdistribution) HRs and confidence intervals.
|
From randomization until distant metastasis (clinical and/or radiographic appearance of disseminated disease) or death from any cause, assessed up to 5 years
|
|
Distant metastasis
Time Frame: Up to 5 years
|
Will also be analyzed under a competing risks framework, treating death without experiencing the event in question as a competing risk.
|
Up to 5 years
|
|
Local-regional progression
Time Frame: From randomization to local or regional recurrence ignoring biochemical failure and distant recurrence and censoring for death, assessed up to 5 years
|
Will also be analyzed under a competing risks framework, treating death without experiencing the event in question as a competing risk.
|
From randomization to local or regional recurrence ignoring biochemical failure and distant recurrence and censoring for death, assessed up to 5 years
|
|
PSA nadir during first year of treatment and prior to initiation of any hormonal salvage therapy
Time Frame: During first year of treatment
|
Will be compared between the two groups using a two-sample t-test.
|
During first year of treatment
|
|
Initiation of salvage hormonal therapy
Time Frame: Up to 5 years
|
Will also be analyzed under a competing risks framework, treating death without experiencing the event in question as a competing risk.
|
Up to 5 years
|
|
Undetectable PSA with a non-castrate testosterone (PSA < 0.1 ng/ml and testosterone >= 50 ng/dl)
Time Frame: 1 year
|
Will be compared using chi square tests.
|
1 year
|
|
Undetectable PSA with a non-castrate testosterone (PSA < 0.1 ng/ml and testosterone >= 50 ng/dl))
Time Frame: 3 years
|
Will be compared using chi square tests.
|
3 years
|
|
Acute physician-reported morbidity (per the Common Terminology Criteria for Adverse Events [CTCAE] version 5)
Time Frame: Up to 30 days after radiation therapy
|
Adverse events will be scored according to the National Cancer Institute (NCI)'s CTCAE version 5.0.
For each type of adverse event, counts and frequencies will be provided for the worst grade experienced by the patient by treatment arm.
The proportion of patients with grades >= 1 and >= 3 will be compared between groups using a chi-square test, or Fisher's exact test if cell frequencies are < 5, at the two-sided 0.05 significance level.
Logistic regression, both univariate and multivariate, will be used to model the probability of grade 3+ acute adverse events as a function of treatment arm and covariates.
Both unadjusted and adjusted odds ratios and the respective 95% confidence intervals will be computed.
|
Up to 30 days after radiation therapy
|
|
Late physician-reported morbidity (per the CTCAE version 5) defined as grade 3+ adverse events occurring more than 30 days after the completion of radiation therapy
Time Frame: From the time protocol treatment started to the time of the first recorded late grade 3+ adverse event, assessed up to 5 years
|
Adverse events will be scored according to the NCI's CTCAE version 5.0.
For each type of adverse event, counts and frequencies will be provided for the worst grade experienced by the patient by treatment arm.
The proportion of patients with grades >= 1 and >= 3 will be compared between groups using a chi-square test, or Fisher's exact test if cell frequencies are < 5, at the two-sided 0.05 significance level.
|
From the time protocol treatment started to the time of the first recorded late grade 3+ adverse event, assessed up to 5 years
|
|
Testosterone levels
Time Frame: Every 3 months until 6 months post treatment
|
Testosterone levels will be assessed.
|
Every 3 months until 6 months post treatment
|
|
Acute patient-reported morbidity symptomatic adverse events (per the patient reported outcomes [PRO]-CTCAE)
Time Frame: Up to 5 years
|
Adverse events will also be assessed using PRO-CTCAE items.
Assessments will be collected before and at the end of radiotherapy treatment and in follow-up.
For each symptom and each domain (i.e., frequency, severity, and interference), counts and frequencies will be provided for the worst score experienced by the patient by treatment arm.
The proportion of patients with scores >= 1 and >= 3 will be compared between groups using a chi-square test, or Fisher's exact test if cell frequencies are < 5.
|
Up to 5 years
|
|
Late patient-reported morbidity symptomatic adverse events (per the PRO-CTCAE)
Time Frame: Up to 5 years
|
Adverse events will also be assessed using PRO-CTCAE items.
Assessments will be collected before and at the end of radiotherapy treatment and in follow-up.
For each symptom and each domain (i.e., frequency, severity, and interference), counts and frequencies will be provided for the worst score experienced by the patient by treatment arm.
The proportion of patients with scores >= 1 and >= 3 will be compared between groups using a chi-square test, or Fisher's exact test if cell frequencies are < 5.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Felix Y Feng, NRG Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Prostatic Neoplasms
- Physical Phenomena
- Organizations
- Health Care Economics and Organizations
- Radiation
- Congresses as Topic
- apalutamide
Other Study ID Numbers
- NRG-GU006 (Other Identifier: CTEP)
- U10CA180868 (U.S. NIH Grant/Contract)
- NCI-2017-01268 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Prostate Carcinoma
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | Recurrent Castration-Sensitive Prostate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate CarcinomaUnited States
-
Mayo ClinicRecruitingBiochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate AdenocarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterCompletedProstate Adenocarcinoma | Recurrent Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingProstate Carcinoma | Recurrent Prostate CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
Clinical Trials on Placebo Administration
-
Laekna LimitedRecruiting
-
Camilo Jose Cela UniversityCompleted
-
MWolztUnknown
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisSouth Korea
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRIActive, not recruiting
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRICompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisSouth Korea
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRICompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnGlioma | Ependymoma | Medulloblastoma | Pineoblastoma | Central Nervous System Sarcoma | Primary Central Nervous System Neoplasm | Malignant Intracranial Germ Cell TumorUnited States
-
M.D. Anderson Cancer CenterTerSera Therapeutics LLCActive, not recruitingLocally Advanced Neuroendocrine Neoplasm | Metastatic Neuroendocrine NeoplasmUnited States